Moreover, the 36-month beta value for TRVI is 0.53. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TRVI is 69.87M and currently, short sellers hold a 10.05% of that float. On June 20, 2025, TRVI’s average trading volume was 1.76M shares.
TRVI) stock’s latest price update
Trevi Therapeutics Inc (NASDAQ: TRVI) has seen a decline in its stock price by -0.82 in relation to its previous close of 6.12. However, the company has experienced a -2.88% decline in its stock price over the last five trading sessions. https://www.defenseworld.net reported 2025-06-11 that Squarepoint Ops LLC acquired a new stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 14,059 shares of the company’s stock, valued at approximately $58,000. Other hedge funds and other institutional investors also recently made changes to their positions in the company. Summit Investment Advisors Inc. lifted its holdings in shares of Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock valued at $26,000 after acquiring an additional 2,894 shares during the period. Raymond James Financial Inc. bought a new position in shares of Trevi Therapeutics during the fourth quarter valued at $49,000. Two Sigma Advisers LP bought a new position in shares of Trevi Therapeutics during the fourth quarter valued at $66,000. Cantor Fitzgerald L. P. bought a new position in shares of Trevi Therapeutics during the fourth quarter valued at $82,000. Finally, ProShare Advisors LLC lifted its holdings in shares of Trevi Therapeutics by 86.4% during the fourth quarter. ProShare Advisors LLC now owns 20,685 shares of the company’s stock valued at $85,000 after acquiring an additional 9,589 shares during the period. 95.76% of the stock is owned by institutional investors. Analyst Ratings Changes A number of brokerages have issued reports on TRVI. Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $9.00 to $29.00 in a report on Monday, March 10th. Wall Street Zen lowered Trevi Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, June 6th. HC Wainwright began coverage on Trevi Therapeutics in a research note on Wednesday, May 28th. They issued a “buy” rating and a $21.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $24.00 target price on shares of Trevi Therapeutics in a research note on Tuesday, May 20th. Finally, B. Riley restated a “buy” rating and issued a $20.00 target price (up from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $18.63. Read Our Latest Research Report on Trevi Therapeutics Insider Buying and Selling In other news, CEO Jennifer L. Good sold 5,263 shares of the business’s stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $6.58, for a total transaction of $34,630.54. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares in the company, valued at approximately $1,403,599.54. The trade was a 2.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 18.30% of the company’s stock. Trevi Therapeutics Stock Up 1.6% Shares of TRVI stock opened at $6.51 on Wednesday. The stock has a 50-day moving average price of $6.27 and a 200 day moving average price of $5.05. The firm has a market cap of $650.30 million, a price-to-earnings ratio of -14.80 and a beta of 0.59. Trevi Therapeutics, Inc. has a 12 month low of $2.36 and a 12 month high of $7.48. Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.04. Sell-side analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year. About Trevi Therapeutics (Free Report) Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
TRVI’s Market Performance
TRVI’s stock has fallen by -2.88% in the past week, with a monthly drop of -6.47% and a quarterly drop of -10.87%. The volatility ratio for the week is 3.12% while the volatility levels for the last 30 days are 4.44% for Trevi Therapeutics Inc The simple moving average for the last 20 days is -3.95% for TRVI stock, with a simple moving average of 34.17% for the last 200 days.
Analysts’ Opinion of TRVI
Many brokerage firms have already submitted their reports for TRVI stocks, with H.C. Wainwright repeating the rating for TRVI by listing it as a “Buy.” The predicted price for TRVI in the upcoming period, according to H.C. Wainwright is $21 based on the research report published on May 28, 2025 of the current year 2025.
Raymond James, on the other hand, stated in their research note that they expect to see TRVI reach a price target of $29, previously predicting the price at $9. The rating they have provided for TRVI stocks is “Strong Buy” according to the report published on March 10th, 2025.
Needham gave a rating of “Buy” to TRVI, setting the target price at $25 in the report published on March 10th of the current year.
TRVI Trading at -3.79% from the 50-Day Moving Average
After a stumble in the market that brought TRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.85% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TRVI starting from SCIASCIA THOMAS, who sale 2,631 shares at the price of $6.60 back on Mar 25 ’25. After this action, SCIASCIA THOMAS now owns 221,373 shares of Trevi Therapeutics Inc, valued at $17,365 using the latest closing price.
GOOD JENNIFER L, the President & CEO of Trevi Therapeutics Inc, sale 5,263 shares at $6.58 during a trade that took place back on Mar 21 ’25, which means that GOOD JENNIFER L is holding 213,313 shares at $34,625 based on the most recent closing price.
Stock Fundamentals for TRVI
The total capital return value is set at -0.51. Equity return is now at value -55.12, with -51.03 for asset returns.
Based on Trevi Therapeutics Inc (TRVI), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -43.12. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -17029.67.
Currently, EBITDA for the company is -51.52 million with net debt to EBITDA at 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.38.
Conclusion
To wrap up, the performance of Trevi Therapeutics Inc (TRVI) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
